Stira Company Profile

What is the competitive landscape for STIRA

STIRA has four approved drugs.

Summary for Stira

US Patents:	0
Tradenames:	4
Ingredients:	4
NDAs:	4

Drugs and US Patents for Stira

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Stira	SELENIOUS ACID	selenious acid	SOLUTION;INTRAVENOUS	218536-001	Dec 31, 2025	AP	RX	No	No
Stira	CUPRIC CHLORIDE	cupric chloride	INJECTABLE;INJECTION	217626-001	Apr 30, 2024	AP	RX	No	No
Stira	ZINC SULFATE	zinc sulfate	SOLUTION;INTRAVENOUS	217624-002	Jun 10, 2025	AP	RX	No	No
Stira	SELENIOUS ACID	selenious acid	SOLUTION;INTRAVENOUS	218536-002	Dec 31, 2025	AP	RX	No	No
Stira	ZINC SULFATE	zinc sulfate	SOLUTION;INTRAVENOUS	217624-003	Jun 10, 2025	AP	RX	No	No
Stira	ZINC CHLORIDE	zinc chloride	INJECTABLE;INJECTION	217625-001	Apr 14, 2025	AP	RX	No	No

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Stira

Last updated: June 7, 2026

Stira Competitive Landscape Analysis: Market Position, Patent Strength, FDA Pathway Risk, and Generic Entry Scenarios

Stira’s competitive positioning depends on (1) its regulatory pathway status in the US, (2) the depth of its Orange Book patent listings (drug substance, drug product, and method-of-use), and (3) whether competing products can enter through Paragraph IV generics or biosimilar-like pathways (if applicable). A credible competitive landscape view requires mapping Stira’s FDA approval package to listed patents, then tracking expiration and litigation posture to forecast launch timing, design-arounds, and licensing leverage.

No sufficient source data was provided to identify the active ingredient(s) in “Stira,” its dosage forms, FDA approval date, US exclusivities, Orange Book listings, patent numbers, assignees, or any pending Paragraph IV litigation. Without those specifics, a complete and accurate patent-and-competition analysis cannot be produced.

References

No sources were provided.